187 related articles for article (PubMed ID: 24245483)
21. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
Senel F
Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
[TBL] [Abstract][Full Text] [Related]
22. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
23. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
24. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
27. Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
Payandeh M; Sadeghi M; Sadeghi E; Madani SH
Asian Pac J Cancer Prev; 2016; 17(3):1261-4. PubMed ID: 27039757
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with HER2 overexpression in breast cancer: Experience in an Asian developing country.
Tan GH; Choo WY; Taib NA; Yip CH
Asian Pac J Cancer Prev; 2009; 10(5):837-40. PubMed ID: 20104975
[TBL] [Abstract][Full Text] [Related]
30. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
31. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
[TBL] [Abstract][Full Text] [Related]
32. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
33. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
35. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
36. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
37. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
38. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
39. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
40. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.
Caldarella A; Crocetti E; Bianchi S; Vezzosi V; Urso C; Biancalani M; Zappa M
Pathol Oncol Res; 2011 Sep; 17(3):753-8. PubMed ID: 21479875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]